Moderne Diagnosekonzepte für gastroenteropankreatische NET

• Literatur

• 1 Brazeau P. Vale W. et al. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973; 179: 77-79
• 2 Reisine T. Bell GI. Molecular biology of somatostatin receptors. Endocr Rev 1995; 16: 427-442
• 3 Behr TM. Kann PH. Gotthardt M. et al. Nuklearmedizinische Diagnostik und Therapie neuroendokriner Tumoren des Gastrointestinaltraktes einschließlich des Karzinoides. Der Nuklearmediziner 2003; 26: 121-133
• 4 Krenning EP. Bakker WH. Breeman WA. et al. Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet 1989; 8632: 242-244
• 5 Lamberts SW. Koper JW. Reubi JC. et al. Potential role of somatostatin analogues in the treatment of cancer. European Journal of Clinical Investigation 1987; 17: 281-287
• 6 Reubi JC. Neuropeptide receptors in health and disease: the molecular basis for in vivo imaging. [see comment]. J Nucl Med 1995; 36: 1825-1835
• 7 Caplin ME. Pavel M. Ćwikła JB. et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med 2014; 371: 224-233
• 8 Rinke A. Mueller HH. Schade-Brittinger C. et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009; 27: 4656-4663
• 9 Denzler B. Reubi JC. Expression of somatostatin receptors in peritumoral veins of human tumors. Cancer 1999; 85: 188-198
• 10 Ivancevic V. Wormann B. Nauck C. et al. Somatostatin receptor scintigraphy in the staging of lymphomas. Leukemia & Lymphoma 1997; 26: 107-114
• 11 Krenning EP. Kwekkeboom DJ. Bakker WH. et al. Somatostatin receptor scintigraphy with [In-111-DTPA-D-Phe1]- and [123I-Tyr3]-Octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993; 20: 716-731
• 12 Seregni E. Chiti A. Bombardierei E. et al. Radionuclide imaging of neuroendocrine tumours: biological basis and diagnostic results. Eur J Nucl Med 1998; 25: 639-658
• 13 Hofland LJ. Lamberts SW. Somatostatin receptor subtype expression in human tumors. Ann Oncol 2001; 12 (Suppl. 02) S31-S36
• 14 Gabriel M. Decristoforo C. Donnemiller E. et al. An intrapatient comparison of 99mTc-EDDA/HYNIC-TOC with In-111-DTPA-octreotide for diagnosis of somatostatin receptor-expressing tumors. J Nucl Med 2003; 44: 708-716
• 15 Gabriel M. Decristoforo C. Kendler D. et al. Ga-68-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 2007; 48: 508-518